Aadi Bioscience, Inc. (NASDAQ:AADI) Q3 2023 Earnings Call Transcript

Dave Lennon: Yeah. And then in the interim, we won’t be presenting co-mutation status at this point in time. The numbers, while significant in terms of an initial indicative nature of how the trial is going, we don’t believe would be sufficient to really do a detailed analysis of co-mutation status that would be robust enough to make any determinations on at this point. So, we won’t be sharing that data.

Ahu Demir: That’s helpful. And my second question is on the endometrial program. Now the trial is enrolling, how many sites are open? And when do you expect to see initial data from Stage 1 portion of the study?

Dave Lennon: So we’ve just started that study. I wouldn’t comment on the number of sites we have, but the community is very excited about engaging in this study and we hope to have an update on the study sometime in 2024.

Ahu Demir: Great. Thank you for taking my questions.

Dave Lennon: Thanks, Ahu.

Operator: And I’m not showing any further questions at this time. I’d like to turn the call back over to Dave for any closing remarks.

Dave Lennon: Super. Thank you very much, Kevin and thank you, everyone for joining us on today’s call. As we mentioned, we’re really excited about the progress we’re making on the PRECISION 1 trial with the interim analysis plan for mid-December and a number of exciting catalysts for 2024 that could propel our need to grow. We appreciate your time and look forward to the opportunities in the future to provide additional updates on our process – or progress, I should say. Thank you for joining the call and have a great day, everyone.

Operator: Ladies and gentlemen, this does conclude today’s presentation. You may now disconnect and have a wonderful day.